Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
Type: Investor Group Dinner
Date/Time:
Type: Fireside Chat Presentation
Date/Time:
Title: Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS with TRiM™ SC
Date/Time:
Presenter: Kayal Madhivanan
33rd
Title: Elevated Activin E levels correlate with insulin resistance and metabolic dysfunction in non-human primates and adult patients with obesity and type 2 diabetes
Date/Time:
Presenter:
2026
Type: Fireside Chat Presentation
Date/Time:
2 Oral Presentations:
Title: PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF PLOZASIRAN IN SUBJECTS WITH RENAL OR HEPATIC IMPAIRMENT
Session: Late Breaker Clinical Abstracts
Date/Time:
Presenter:
Title: A CASE REPORT OF A PREGNANT WOMAN WITH FAMILIAL CHYLOMICRONEMIA SYNDROME TREATED WITH PLOZASIRAN, A SMALL INTERFERING RNA AGAINST APOC3
Session: EAS stage: Outreach and case presentations
Date/Time:
Presenter:
Title: ARO‑INHBE demonstrates clinically meaningful reductions in liver fat as monotherapy and in combination with low-dose tirzepatide in adults with obesity
Late Breaker Poster Session
Presenter:
Presentation materials and webcast links, if applicable, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About
For more information, please visit arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company’s email list and receive news directly, please visit ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20260504575415/en/
626-304-3400
ir@arrowheadpharma.com
Investors:
212-915-2578
britchie@lifesciadvisors.com
Media:
724-910-9389
kguarinoni@lifescicomms.com
Source: